Akero’s FGF21 analog yields 63 percent to 72 percent relative hepatic fat reduction in Phase 2a study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase 3 NASH readout. FGF21 analogs comprise one of the more crowded classes in nonalcoholic steatohepatitis (NASH) … Continue reading “Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data”